Viridian Therapeutics, Inc.\DE
Nasdaq · Healthcare · Pharmaceutical Preparations · Waltham, MA
VRDN chart
What traders are saying about $VRDN
Latest postsViridian Therapeutics, Inc.\DE news
- Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
Yahoo Finance ·
- A live call on Viridian's Q3 results is set for 8 a.m. Nov. 4
Stock Titan ·
- Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base
Yahoo Finance ·
- Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says
Yahoo Finance ·
- Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Yahoo Finance ·
- Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says
Yahoo Finance ·
- Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Yahoo Finance ·
- Graves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight
Yahoo Finance ·
- Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)
Yahoo Finance ·
- Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich?
Yahoo Finance ·
- Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today
Yahoo Finance ·
- “Stay Invested”: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market
Yahoo Finance ·
Viridian Therapeutics, Inc.\DE key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$342.6M | -$269.9M | -$237.7M | -$129.9M |
| Diluted EPS | – | – | $-5.31 | $-4.05 |
| Total assets (year end) | $899.4M | $742.4M | $490.4M | $435.1M |
| Cash and equivalents (year end) | – | – | – | – |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Viridian Therapeutics, Inc.\DE
- Ticker
- VRDN (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1590750
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
Frequently asked questions
What exchange is Viridian Therapeutics, Inc.\DE listed on?
Viridian Therapeutics, Inc.\DE trades on the Nasdaq under the ticker symbol VRDN.
What industry is Viridian Therapeutics, Inc.\DE in?
Viridian Therapeutics, Inc.\DE is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Viridian Therapeutics, Inc.\DE headquartered?
Viridian Therapeutics, Inc.\DE's business address on file with the SEC is in Waltham, MA.
When does Viridian Therapeutics, Inc.\DE's fiscal year end?
Viridian Therapeutics, Inc.\DE's fiscal year ends on December 31.
How much revenue did Viridian Therapeutics, Inc.\DE report?
Viridian Therapeutics, Inc.\DE reported $4.0M in revenue for calendar year 2017, according to its SEC filings.